Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, the company’s lead engineered HSC therapeutic candidate for the treatment of acute myeloid leukemia (AML).
[Vor Biopharma]
7992332
{7992332:nan}
apa
50
1
166610
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
